Q4 2019 13F Holders as of 31 Dec 2019
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
90,438,636
-
Number of holders
-
248
-
Total 13F shares, excl. options
-
31,537,408
-
Shares change
-
+3,950,529
-
Total reported value, excl. options
-
$1,920,718,365
-
Value change
-
+$255,276,153
-
Put/Call ratio
-
147%
-
Number of buys
-
140
-
Number of sells
-
68
-
Price
-
$60.90
Institutional Holders of CRISPR Therapeutics AG - Common Stock (CRSP) as of Q4 2019
As of 31 Dec 2019 CRISPR Therapeutics AG - Common Stock (CRSP) had 248 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 31,537,408 shares of stock of the company.
Largest 10 holders included Versant Venture Management, LLC, Nikko Asset Management Americas, Inc., ARK Investment Management LLC, NEA Management Company, LLC, FEDERATED HERMES, INC., PRICE T ROWE ASSOCIATES INC /MD/, WADDELL & REED FINANCIAL INC, Cormorant Asset Management, LP, FMR LLC, and ORBIMED ADVISORS LLC.
This table shows 248 institutional shareholders of the security as of 31 Dec 2019.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.